Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1983

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

A new ultra-low-dose combination oral contraceptive.

AUTHORS

Woutersz TB

SOURCE

Journal of Reproductive Medicine. 1983 Jan;28(1 Suppl):81-4.

ABSTRACT

Compilation of recent data on 1130 female volunteers from 17 US sites enrolled in a study of a new low dose

combination oral contraceptive (OC) containing .15 mg levonorgestrel and .03 mg ethinyl estradiol are reported. All

clients had complete histories and physical examinations at entrance and at 6 month intervals during treatment, and

about 20% also had blood sugar, blood urea nitrogen, and liver profile determinations. Follow-up evaluation was

performed after the 1st and 3rd cycles and every 3 cycles thereafter to determine patterns of pill taking, bleeding

episodes, untoward effects, and concomitant medication. Clients ranged in age from 15-40 with mean age of 23.6;

76.1% were white, 11.9% black, 7.5% Hispanic, and 4.4% Oriental. 61.9% were of proven fertility and 92% had regular

cycles. 48.1% of the study population had not used female hormones or been pregnant within 60 days of enrollment.

A total of 11,064 cycles over a maximum 31 cycles of treatment are reported. Despite 1-6 or more missed pills in

1623, or 14.7% of the cycles, only 3 pregnancies were reported, only 1 presumed to be a method failure, for a use-

effectiveness Pearl index of .35/100 women years of usage. Use of the formulation resulted in a mean cycle length

of 28.5 days. 92.7% of cycles ranged from 26-30 days, almost equal to pretreatment values. The frequency of light

menstrual flows increased. Breakthrough bleeding was reported in 669 cycles, or 6.0%, while spotting occurred in

852 cycles, or 7.7%. Amenorrhea was reported after 194 cycles (1.8%). No reports of post-pill amenorrhea were

made. Incidence of side effects was very low. Only acne, breast discomfort, dysmenorrhea, gastrointestinal

symptoms, headache, nausea, and vaginal discharge were reported in more than 1.0% of cycles. The pill had

essentially no effect on weight or blood pressure, and produced no clinically significant laboratory abnormalities in

hematology, urine, blood sugar, blood urea nitrogen, or liver profile determination. A total of 515 subjects (45.6%)

discontinued use of the drug for various nonmedical reasons. Another 146 women (12.9%) discontinued use and

gave medical reasons; 132, or 11.7%, were commonly reported side effects of OCs such as breakthrough bleeding,

headache, and nausea. Clinical trials with the formulation have shown it to be a safe and effective ultra-low dose

combined OC agent whose mode of action is primarily gonadotropin suppression and subsequent anovulation.

(PubHealth.info Document ID: CONT5T 2036-06)

PubHealth.info NOTE: The author(s) of this article titled, "A new ultra-low-dose combination oral contraceptive.",

is(are) Woutersz TB. The source of this article is "Journal of Reproductive Medicine. 1983 Jan;28(1 Suppl):81-4.".

This article was published in 1983 in English language(s). (PubHealth.info® Document ID: CONT5T 2036-06. All

rights reserved with PubHealth.info) PIN: 22036

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.